GLPwatch
Evaluation of glucagon-like peptide-1 receptor expression in nondiabetic and diabetic atherosclerotic mice using PET tracer <sup>68</sup>Ga-NODAGA-exendin-4.
Am J Physiol Endocrinol Metab · 2021
Last updated 2026-05-28In a study on mice with artery disease, researchers used a special imaging tool to detect GLP-1 receptors in inflamed areas of the arteries. The tool worked in both mice with and without diabetes, and the receptors were mostly found in a type of immune cell called M2 macrophages.
AI summary of the abstract below.
| Journal | Am J Physiol Endocrinol Metab, 2021 |
|---|---|
| Citations | 10 |
| Relative citation ratio | 0.68 |
| NIH percentile | 38 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Cardiovascular Risk Reduction |
Abstract
Cardiovascular effects of glucagon-like peptide-1 receptor (GLP-1R) agonist therapies are potentially mediated by anti-inflammatory effects on atherosclerosis. Our study demonstrates that Ga-NODAGA-exendin-4, a radioligand specifically targeting GLP-1R, detects GLP-1R expression in inflamed atherosclerotic lesions in nondiabetic and diabetic hypercholesterolemic mice. Immunofluorescence staining suggests that GLP-1R is primarily localized in M2 macrophages in lesions. This study describes a new potential tool that may have translational relevance for studies of pharmacological modification of GLP-1R signaling in atherosclerosis.
Verbatim abstract via PubMed 33843281 ↗